UK Markets closed

Cyteir Therapeutics, Inc. (CYT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.5600+0.0600 (+2.40%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 88.53M
Enterprise value -76.97M
Trailing P/E 0.47
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.55
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-87.20%
S&P500 52-week change 3-2.16%
52-week high 321.6900
52-week low 31.5550
50-day moving average 32.8195
200-day moving average 36.1627

Share statistics

Avg vol (3-month) 3140.24k
Avg vol (10-day) 377.54k
Shares outstanding 535.41M
Implied shares outstanding 6N/A
Float 811.31M
% held by insiders 111.56%
% held by institutions 170.65%
Shares short (28 Jul 2022) 4401.52k
Short ratio (28 Jul 2022) 45.92
Short % of float (28 Jul 2022) 42.10%
Short % of shares outstanding (28 Jul 2022) 41.14%
Shares short (prior month 29 Jun 2022) 4525.27k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-16.60%
Return on equity (ttm)-27.82%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -49.38M
Net income avi to common (ttm)-49.74M
Diluted EPS (ttm)5.4800
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)166.4M
Total cash per share (mrq)4.71
Total debt (mrq)2.84M
Total debt/equity (mrq)1.73
Current ratio (mrq)19.95
Book value per share (mrq)4.64

Cash flow statement

Operating cash flow (ttm)-45.59M
Levered free cash flow (ttm)-28.49M